SCHEMBL4239132

SCHEMBL4239132

NC(=O)C(C(=O)Nc1ncc[nH]1)c1cccc(Cl)c1

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ FFAR2 O15552 1/20 0.52
▸ ROCK2 O75116 4/20 0.40
▸ PTGES O14684 3/20 0.40
▸ ADRA1D P25100 2/20 0.40
▸ ADRA2A P08913 1/20 0.40
▸ ADRA2C P18825 1/20 0.40
▸ ADRA1A P35348 1/20 0.40
▸ ADRA1B P35368 1/20 0.40
▸ AURKA O14965 2/20 0.39
▸ ITGB3 P05106 1/20 0.36
▸ ITGAV P06756 1/20 0.36
▸ GRM4 Q14833 1/20 0.36
▸ HDAC6 Q9UBN7 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ RPS6KB1 P23443 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4240812 0.85 FFAR2 (0.44) FFAR2ROCK2PTGESAURKAITGB3
SCHEMBL4239786 0.85 FFAR2 (0.67) FFAR2PTGESADRA1DADRA2AADRA2C
SCHEMBL4247079 0.84 FFAR2 (0.49) FFAR2PTGESADRA1DADRA2AADRA2C
SCHEMBL4239414 0.82 FFAR2 (0.41) FFAR2ROCK2AURKA
SCHEMBL4240719 0.78 FFAR2 (0.51) FFAR2ROCK2PTGESADRA1DADRA2A
SCHEMBL4242694 0.77 FFAR2 (0.50) FFAR2ROCK2PTGESHDAC6
SCHEMBL4242107 0.77 FFAR2 (0.53) FFAR2PTGESAURKARPS6KB1
SCHEMBL4240372 0.77 FFAR2 (0.44) FFAR2PTGESRPS6KB1
SCHEMBL4243620 0.76 FFAR2 (0.43) FFAR2PTGESADRA2AADRA2C
SCHEMBL4244243 0.74 FFAR2 (0.50) FFAR2ROCK2ADRA1DADRA2AADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060223849-A1 Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC 2006-10-05 — — US claimed
US-8946259-B2 Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC (US) 2015-02-03 — — US disclosed
US-20140066477-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors HIGH POINT PHARMACEUTICALS, LLC (US) 2014-03-06 — — US disclosed
US-8598353-B2 Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC (US) 2013-12-03 — — US disclosed
EP-2457901-A1 Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors High Point Pharmaceuticals, LLC (US) 2012-05-30 — — EP disclosed
US-20090326006-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors VTVX HOLDINGS II LLC 2009-12-31 — — US disclosed
US-20060223849-A1 Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC 2006-10-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326006-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors BACE1, BACE2, APP FFAR2 4632/4885ROCK2 3092/4885PTGES 2022/4885
US-20060223849-A1 Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors BACE1, BACE2, APP FFAR2 4632/4885ROCK2 3092/4885PTGES 2022/4885
US-20140066477-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors BACE1, BACE2, APP FFAR2 4632/4885ROCK2 3092/4885PTGES 2022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback